Dr. Tanioka on the Results of CALGB 40601 in HER2+ Breast Cancer

Maki Tanioka, MD, PhD
Published Online: Tuesday, Mar 07, 2017



Maki Tanioka, MD, PhD, UNC Lineberger Comprehensive Cancer Center, discusses the results of the phase III CALGB 40601 (Alliance) study in HER2-positive breast cancer.

This study was an integrated analysis of multidimensional genomic data that explored neoadjuvant weekly paclitaxel and trastuzumab (Herceptin) with or without lapatinib (Tykerb).

Results showed that tumor genetics, RNA subtype, and the microenvironment were independently predictive of response to trastuzumab-containing therapies. According to Tanioka, these results support integrating RNA- and DNA-based tumor assessments to determine response to HER2-targeting.
 


Maki Tanioka, MD, PhD, UNC Lineberger Comprehensive Cancer Center, discusses the results of the phase III CALGB 40601 (Alliance) study in HER2-positive breast cancer.

This study was an integrated analysis of multidimensional genomic data that explored neoadjuvant weekly paclitaxel and trastuzumab (Herceptin) with or without lapatinib (Tykerb).

Results showed that tumor genetics, RNA subtype, and the microenvironment were independently predictive of response to trastuzumab-containing therapies. According to Tanioka, these results support integrating RNA- and DNA-based tumor assessments to determine response to HER2-targeting.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections: 15th Annual International Congress on the Future of Breast Cancer®Oct 06, 20172.0
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
Publication Bottom Border
Border Publication